medigraphic.com

2012, Number 5

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2012; 50 (5)

Guillain-Barre syndrome. Its association with the alpha tumoral necrosis

Soto-Cabrera E, Hernández-Martínez A, Yáñez H, Carrera R

Language: Spanish
References: 16
Page: 565-567
PDF size: 124.01 Kb.


ABSTRACT

Background: adalimumab, a human recombinant monoclonal antibody against tumoral necrosis factor alpha (TNFα), has been associated with central nervous system demyelinating diseases and peripheral neuropathic syndrome. The Guillain-Barré Syndrome (GBS) is one of them.
Clinical case: we presented the case of a 65 years woman, with diabetes mellitus and psoriasic arthritis, treated with adalimumab; after the fourth infusion, she developed paresthesia and mild weakness in lower limbs, these symptoms persisted three days after each infusion and each time remitted spontaneously; following the eight dose, presented a characteristic clinical picture of the GBS, confirmed with neurophysiological studies that showed an axonal motor-sensitive polyneuropathy. The treatment consisted in intravenous immunoglobulin, with good outcome.
Conclusions: the synergy among cellular and humoral immune responses, against peripheral nerve antigens is responsible of immunopathogenesis related to GBS. The prolonged and intensified pathologic immune response induced by adalimumab, may be associated to the development of GBS.


REFERENCES

  1. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during antitumor necrosis factor alpha therapy for inflammatory arthritis. Arthritis Rheum 2001;44(12):2862-2869.

  2. Simsek I, Erdem H, Pay S, Sobaci G, Dinc A. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2007;66(9):1255-1258. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/17456525/ ?tool=pubmed

  3. Ahmed M, Luggen M, Herman JH, Weiss KL, Decourten- Myers G, Quinlan JG, et al. Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration. J Rheumatol 2006;33(11):2344-2346.

  4. Gil C, Legido J, Cuenca C, Santamaría A, Sacristán MV, Salvatierra C, et al. Meningitis due to Listeria monocytogenes during adalimumab therapy. Gastroenterol Hepatol 2009;32(8):587-588.

  5. Sillero-Sánchez M, García-Domínguez G, Asencio-Marchante JJ. Demyelinating encephalomyelitis associated with treatment with adalimumab. Neurologia 2010;25:136-138. Disponible en http://www.elsevier.es/es/revistas/ neurologia-295/encefalomielitis-desmielinizante-asociadaal- tratamiento-adalimumab-13150558-cartas-al-editor- 2010

  6. Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain–Barré and Miller-Fisher syndromes occurring with tumor necrosis factor alpha, antagonist therapy. Arthritis Rheum 2006;54(5):1429-1434. Disponible en http:// onlinelibrary.wiley.com/doi/10.1002/art.21814/full

  7. Kurmann PT, Van Lindthoudt D, So AK. Miller–Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab. Clin Rheumatol 2009;28(1):93-94.

  8. Silburn S, McIvor E, McEntegart A, Wilson H. Guillain–Barré syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature. Ann Rheum Dis 2008;67(4):575-576.

  9. Singer OC, Otto B, Steinmetz H, Ziemann U. Acute neuropathy with multiple conduction blocks after TNF alpha monoclonal antibody therapy. Neurology 2004;63(9): 1754.

  10. Alshekhlee A, Basiri K, Miles JD, Ahmad SA, Katirji B. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists. Muscle Nerve 2010;41(5):723-727.

  11. Hartung HP, Hughes RA, Taylor WA, Heininger K, Reiners K, Toyka KV. T cell activation in Guillain-Barre syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology 1990;40(2):215-218.

  12. Stübgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008;37(3):281-292.

  13. Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, et al. Chronic tumor necrosis factor alter T cell responses by attenuating T cell receptor signaling. J Exp Med 1997;185(9):1573-1584. Disponible en http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC2196294/?tool= pubmed

  14. Cope A, Ettinger R, McDevitt H. The role of TNF alpha and related cytokines in the development and function of the autoreactive T cell repertoire. Res Immunol 1997;148 (5):307-312.

  15. Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, et al. Approaches for identifying and defining environmental associated rheumatic disorders. Arthritis Rheum 2000;43(2):243-249.

  16. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor ? antagonism by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001;44(9):1977-1983.




2020     |     www.medigraphic.com